摘要
免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)作为一种免疫疗法,在多种癌症的治疗中发挥着重要作用,同时,其可诱导多种免疫相关不良事件(immune-related adverse events,irAEs)的发生。白细胞介素-6(interleukin-6,IL-6)是一种重要的炎症因子,已被证明可通过多种机制促进癌症进展及影响ICIs的临床应用。本文就细胞因子IL-6如何调节免疫检查点的表达以及对免疫阻断疗法和irAEs的影响进行探讨,总结靶向IL-6信号转导对ICIs功效及irAEs治疗的作用。
Immune checkpoint inhibitors(ICI),an immunotherapy,have an important role in the treatment of various cancers.However,ICIs induce several immune-related adverse events(irAEs).Interleukin(IL)-6 is an important inflammatory factor that promotes cancer progression and modulates the clinical application of ICIs through various mechanisms.Herein,we postulate possible mechanisms that are involved in the ICI-regulatory effects mediated by the expression of the cytokine interleukin-6(IL-6),elucidate the effect of IL-6 on checkpoint-blockade therapy and irAEs,and summarize the role of IL-6 signaling-targeted interventions in ICIs efficacy and irAEs management.
作者
朱玲玲
张亚妮
史婷婷
于晓辉
张久聪
Lingling Zhu;Yani Zhang;Tingting Shi;Xiaohui Yu;Jiucong Zhang(Department of Gastroenterology,The 940th Hospital,PLA Joint Logistic Support Force,Lanzhou 730050,China;First Clinical Medical College,Gansu University of Traditional Chinese Medicine,Lanzhou 730000,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2024年第11期585-589,共5页
Chinese Journal of Clinical Oncology
基金
中央高校优秀青年团队培育项目(编号:1001451201)
甘肃省科技计划项目(编号:21JR7RA017)
中国人民解放军联勤保障部队第九四〇医院院内科研重点项目(编号:2021yxky079)
院内科研拔尖项目(编号:2021yxky002)资助。
关键词
白细胞介素-6
肿瘤
免疫检查点抑制剂
免疫相关不良事件
interleukin-6(IL-6)
tumor
immune checkpoint inhibitors(ICIs)
immune-related adverse events(irAEs)
